RM

RESERVE MEDS

RESERVED FOR YOU.

PATIENT ACCESS BRIEF

Ebglyss in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

DERMATOLOGY · ATOPIC DERMATITIS IL-13

The clinical situation

Ebglyss (lebrikizumab) is an FDA-approved high-affinity monoclonal antibody that binds soluble IL-13 and blocks its assembly of the IL-13Rα1 / IL-4Rα signalling heterodimer, developed by Eli Lilly. Indicated for moderate-to-severe atopic dermatitis in adults and adolescents inadequately controlled with topical therapies or who have not responded adequately to a previous systemic therapy or biologic. Administration is subcutaneous: a loading phase followed by every-two-weeks maintenance through week 16, with step-down to every-four-weeks maintenance for patients who achieve clear or almost-clear skin at week 16. Ebglyss's mechanism — blocking soluble IL-13 specifically — is distinct from dupilumab's IL-4Rα blockade and from tralokinumab's different IL-13 binding profile.

The pathway, 5 steps

1. **Consultation & clinical rationale.** Your treating dermatologist documents severity, prior therapies, and the clinical case for Ebglyss over alternatives.
2. **SFDA named-patient application.** Your dermatologist or the importing pharmacy files the clinical rationale, Saudi licence verification, patient reference, product details, and chain-of-custody plan.
3. **US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner under documented chain of custody.
4. **Cold-chain shipment & arrival.** Temperature-controlled transport; the importer of record receives and hands off per your dermatologist's protocol.
5. **Initiation & re-supply cadence.** Most patients or caregivers self-inject at home after training; Reserve Meds supports the loading, q2w, and q4w step-down cadence.

Indicative economics

Reference US cash-pay range: USD 3,500–4,000 per month at loading and q2w maintenance (the q4w step-down schedule reduces monthly cost for eligible responders; Reserve Meds issues a transparent delivered quote at intake).

Indicative first-shipment timing

10–21 days from a complete SFDA application to first shipment, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Physician documentation kit keyed to SFDA review. **Logistics.** Cold-chain shipment with importer-of-record handling. **Concierge case lead.** Named point

of contact for family and dermatology team; we coordinate around pilgrimage, fasting, and clinic scheduling to minimise disruption. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating dermatologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Ebglyss × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemeds.com/access-guides/ebglyss-saudi-arabia.html

SCAN TO JOIN

reservemeds.com · hello@reservemeds.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team